Scientist I, Translational Research

See more jobs from Flagship Pioneering

over 2 years old

This job is no longer active

Company Summary:

Ring Therapeutics Inc. is a privately held, early-stage biotechnology company pioneering a completely novel form of gene therapy by exploiting a family of naturally occurring commensal viruses to create the first redosable and targetable DNA medicines. This approach enables a powerful new class of tropic, persistent, non-integrating vectors that overcome the immunogenicity, and limited tropism of existing gene therapy vectors. Ring Therapeutics is leveraging this versatile technology to develop a broad pipeline of novel, targeted medicines for disease with high unmet medical need.

Ring Therapeutics was founded by Flagship Pioneering, focused on launching breakthrough companies based on internally conceived innovations and insights. Flagship Pioneering has created over 40 groundbreaking companies over the past fifteen years, all of which are pioneering novel and proprietary biological, industrial, and engineering approaches to solve major needs in human health and sustainability. These companies include Seres Therapeutics (NASDAQ:MCRB), Moderna (MRNA), Syros Pharmaceuticals (SYRS), Rubius Therapeutics (RUBY), Axcella Health (AXLA), Evelo Biosciences (EVLO), and Indigo Agriculture.

Position Summary:

Ring Therapeutics is seeking an independent and highly motivated in vivo biology Scientist to join the Translational Research team to support the development of novel Anellovector therapeutics. The Translational team is responsible for discovery and validation of cardiac disease targets, and translation to novel therapeutic interventions.

  • The successful candidate will be an integral part of the biology group and will help drive disease indication selection and preclinical studies to support advancement of drug discovery programs to the clinic.
  • Hands-on experience in pre-clinical models of cardiac diseases, and the ability to utilize these models for target validation and mechanism of action studies is required.
  • Experience with cardiac myocyte cell culture and in vivo techniques applied to cardiovascular biology is a plus.
  • The role requires independent planning and execution of experiments, as well as rigorous analysis and interpretation of data to achieve set objectives.
  • Hands-on experience in gene therapy for cardiac diseases is highly desirable. The successful candidate will interface with external parties such as vendors, academic research teams, and contract research organizations as necessary to accelerate development efforts.

This is a great opportunity to participate in the development of cutting-edge gene therapy products. We are searching for an enthusiastic and highly motivated individual who is comfortable multitasking and working both with a team and independently across various aspects of translational research.

Key Responsibilities:

  • Design, execute and interpret in vivo studies to evaluate Ring’s Anellovector expression in rodent models.
  • Function as lead scientist on several gene therapy programs which involves: development and execution of preclinical research studies, collaboratively contribution to project team discussions, facilitate key decisions on therapeutic design, lead candidate selection and dose selection.
  • Study molecular and cell biology relevant to Ring’s Anellovectors.
  • Direct supervision of research associates; support experiment planning and design to key research objectives.
  • Maintain lab notebooks; present and interpret data to the scientific team.

Qualifications:

  • Ph.D. in cell and molecular biology, or closely related field
  • 2-5 years of postdoctoral experience, in academic, pharmaceutical, or biotechnology settings. Industry experience preferred.
  • Experience with:
    • Cardiac disease research.
    • In vivo evaluation of heart biology in rodents.
    • Culturing induced pluripotent stem cells and cardiomyocytes, as well as evaluation of functional endpoints relevant to cardiomyocyte biology.
    • Primary cell isolation from tissue.
 
 
Flagship Pioneering and our ecosystem companies are committed to equal employment opportunity regardless of race, color, ancestry, religion, sex, national origin, sexual orientation, age, citizenship, marital status, disability, gender identity or Veteran status.
 
Recruitment & Staffing Agencies: Flagship Pioneering and its affiliated Flagship Lab companies (collectively, “FSP”) do not accept unsolicited resumes from any source other than candidates. The submission of unsolicited resumes by recruitment or staffing agencies to FSP or its employees is strictly prohibited unless contacted directly by Flagship Pioneering’s internal Talent Acquisition team. Any resume submitted by an agency in the absence of a signed agreement will automatically become the property of FSP, and FSP will not owe any referral or other fees with respect thereto.